药物基本信息
通用名：替奈普酶
适应症：主要用于治疗急性心肌梗死和肺栓塞。
市场需求
替奈普酶（Tenecteplase，TNK）是阿替普酶（alteplase，rtPA）三个位点的变异体。与阿替普酶相比，新型溶栓药物替奈普酶具有半衰期更长、对纤维蛋白特异性更强的特性，并且可以单次推注给药而无需后续输注，这种特性使得替奈普酶的使用更为简单。替奈普酶是第三代纤溶剂，为FDA 批准生产上市的第六个纤溶剂。TNK 0.5 mg/kg已被批准用于急性心肌梗死的治疗，而在急性脑梗死的治疗方面仍处于探索阶段。
英文名：TNKase
The basic information of drug
Common name: Tenecteplase
Indications: treatment of acute myocardial infarction and pulmonary embolism
Market demand
Tenecteplase（TNK）is three loci variants of alteplase (alteplase, rtPA). Compared with alteplase, the new thrombolytic drug, tenecteplase, has a longer half-life, is more specific properties for fibrin, and can be administered alone without subsequent infusion, which makes the use of tenecteplase is simpler. Tenecteplase is the third generation fiber solvent and the sixth fiber solvent approved by the FDA. 0.5 mg / kg TNK has been approved for the treatment of acute myocardial infarction, and it is still in the exploratory stage in the treatment of acute cerebral infarction.
（替奈普酶结构图，图片来源中国科学院）
